Prospective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks

医学 背景(考古学) 动静脉瘘 血液透析 观察研究 前瞻性队列研究 外科 内科学 生物 古生物学
作者
Anukul Ghimire,Anita Lloyd,Susan K. Szigety,José Luis Merino,Karim Alibhai,Gerrit B. Winkelaar,Robert R. Quinn,Marcello Tonelli
出处
期刊:Kidney360 [American Society of Nephrology (ASN)]
标识
DOI:10.34067/kid.0000000650
摘要

Background: Many patients with newly created arteriovenous fistulas (AVF) may die before the AVF is needed for hemodialysis. However, formal competing risks frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary non-function and to describe long-term patency using a competing risk framework. Methods: We did a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary non-function. Secondary outcomes included loss of primary-patency, loss of assisted primary-patency, and loss of secondary functional-patency. Results were presented using icon-array plots to form the basis for future decision aids. Results: Participants were 63.0% male with mean age 62.3 years and median follow-up of 18.5 months (range 0.02-180 months). Of 257 participants, 50 could not be assessed for function or primary non-function, usually due to death. Of the remaining 207, 102 (49.3%) had primary non-function, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of competing risks led to biased results from Kaplan-Meier analyses of lost patency. When accounting for competing risks, loss of primary-patency among AVF with established function was 36.6%, 65.5% and 66.2%, at 1y, 3y and 5y respectively. Conclusions: Only 55% of fistulas were ultimately used for hemodialysis when accounting for competing risks and primary non-function. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
3秒前
李爱国应助逆天子采纳,获得80
4秒前
花痴的幻儿完成签到,获得积分10
4秒前
4秒前
Freya完成签到,获得积分10
5秒前
故酒应助小艾冂学采纳,获得10
7秒前
旺阿旺发布了新的文献求助10
7秒前
tw0125发布了新的文献求助10
8秒前
Freya发布了新的文献求助10
9秒前
淡然思松完成签到,获得积分10
9秒前
顾矜应助科研通管家采纳,获得10
9秒前
CodeCraft应助科研通管家采纳,获得10
9秒前
852应助科研通管家采纳,获得10
9秒前
完美世界应助科研通管家采纳,获得30
9秒前
情怀应助科研通管家采纳,获得10
9秒前
Owen应助科研通管家采纳,获得10
10秒前
CodeCraft应助科研通管家采纳,获得10
10秒前
我是老大应助科研通管家采纳,获得10
10秒前
领导范儿应助科研通管家采纳,获得10
10秒前
丘比特应助科研通管家采纳,获得10
10秒前
赘婿应助科研通管家采纳,获得10
10秒前
完美世界应助科研通管家采纳,获得10
10秒前
SciGPT应助科研通管家采纳,获得10
10秒前
充电宝应助科研通管家采纳,获得10
10秒前
11秒前
12秒前
科研通AI6应助小马采纳,获得10
13秒前
刘嘉欣完成签到 ,获得积分10
13秒前
十二完成签到,获得积分10
14秒前
14秒前
Hello应助温暖的云采纳,获得10
14秒前
14秒前
能干的捕完成签到 ,获得积分10
15秒前
15秒前
量子星尘发布了新的文献求助50
15秒前
tw0125完成签到 ,获得积分10
15秒前
慕青应助TTL采纳,获得10
16秒前
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
NMR in Plants and Soils: New Developments in Time-domain NMR and Imaging 600
Electrochemistry: Volume 17 600
Physical Chemistry: How Chemistry Works 500
SOLUTIONS Adhesive restoration techniques restorative and integrated surgical procedures 500
Energy-Size Reduction Relationships In Comminution 500
Principles Of Comminution, I-Size Distribution And Surface Calculations 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4950591
求助须知:如何正确求助?哪些是违规求助? 4213415
关于积分的说明 13103805
捐赠科研通 3995216
什么是DOI,文献DOI怎么找? 2186825
邀请新用户注册赠送积分活动 1202071
关于科研通互助平台的介绍 1115355